Patients must meet the following criteria to be eligible for CAR T-Cell Immunotherapy:
Patient is well enough to receive CAR T-Cell Immunotherapy.
Tumour has expressed the appropriate marker, e.g. CD19.
An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Absence of disease complications or chemo-toxicity; such as, infection, active GVHD, hyperleucocytosis, severe extra medullary disease.
Last dose of chemotherapy and/or steroid is at least 2 weeks prior; when in doubt, a T-Cell activation test will be performed.
Patient’s tumour burden is as low as possible. In patients with uncontrolled or accelerating tumour burden, induction chemotherapy should be performed first (apheresis should be done prior to commencing the chemotherapy).